


Curriculum Vitae Serena Travaglini



PERSONAL DATA	
Name	Serena Travaglini
Date/place of birth	22-02-1990. Rome, Italy
Citizenship	Italian
Work address	Department of Biomedicine and Prevention, University of Rome "Tor Vergata" Via Montpellier, 1. 00133 Rome, Italy
Phone number	+39 0672596281
e-mail address	serenatravaglini@live.it

EDUCATION			
Tor Vergata University	Rome, Italy	PhD in Biotechnology and Translational Medicine	2017-ongoing
Tor Vergata University	Rome, Italy	Master Degree in Medical Biotechnology	2017
Tor Vergata University	Rome, Italy	Bachelor Degree in Biotechnology	2015

RESEARCH EXPERIENCE		
2015-2017	Undergraduate Student, Tor Vergata University Tutor: F. Lo-Coco/ MT Voso	Oxidative stress and neurodegenerative diseases: role of glutathione and glutathione transferases
2015-2017	Graduate Student, Tor Vergata University Tutor: F. Lo-Coco/ MT Voso	<i>PML/RARα</i> interferes with Nrf2 function in Acute Promyelocytic Leukemia cells
2017-ongoing	PhD Fellow, Tor Vergata University Tutor: F. Lo-Coco/ MT Voso	Molecular characterization of Acute Myeloid Leukemia

RESEARCH INTERESTS
<ul style="list-style-type: none"> • Genetic characterization and multiparameter flow cytometry analysis of leukemia stem cells associated with clonal evolution and disease progression. • Validation of genetic biomarkers in AML/APL as potential therapeutic targets. • Clonal evolution in APL patients resistant to arsenic trioxide. • Evaluation of <i>FLT3</i>-ITD leukemia-associated CD34/CD123/CD25/CD99-positive immunophenotype in patients with APL. • Characterization of the mutational landscape of t(11;17)-positive AML and APL-like leukemias. • Genetic characterization therapy-related AML.

TECHNICAL SKILLS AND COMPETENCES

Molecular Biology Isolation and cryopreservation of high-quality RNA and DNA, PCR, RT-PCR, Q-RT-PCR, Q-LAMP, SNPs analysis, DHPLC, DNA sequencing, cloning and bacterial transformation, NGS technology, droplet digital PCR, site-directed mutagenesis, Western blotting.

Cellular Biology Culture of leukemia cell lines, protein extraction, ELISA, immunofluorescence, FISH, immunoprecipitation, affinity chromatography.

PRESENTATIONS

2019 Poster selection: “Mutational profile of leukemic stem cells in FLT3-ITD mutated AML”. 62nd ASH Annual Meeting – 7-10 December 2019; Orlando, Florida.

2019 Poster presentation: “Mutational profile of leukemic stem cells in FLT3-ITD mutated AML”. 5th International Conference Acute Myeloid Leukemia, ESH 2019 – Estoril, Portugal.

2019 Oral communication: “PROFILO MUTAZIONALE DELLE CELLULE STAMINALI LEUCEMICHE NELLE LAM POSITIVE PER FLT3-ITD”. SIE 2019 – Rome, Italy.

NATIONAL COLLABORATIONS

2019 PRIN to Alessandro Vannucchi, prot. 2017WXR7ZT. “Myeloid Neoplasms: an integrated clinical, molecular and therapeutic approach”.

2018 Project with DIATHEVA company: “CD99 as therapeutic target in AML”.

2018 AIRC 5x1000 to Alessandro Vannucchi, reference code 21267. “Metastatic disease: the key unmet need in oncology”.

PUBLICATIONS

1. NOGUERA NI, BANELLA C, CATALANO G, **TRAVAGLINI S**, DIVONA M, MASCIARELLI S, GUERRERA G, FAZI F, LO-COCO F, VOSO MT AND NOGUERA N. PML/RARA INTERFERES WITH NRF2 TRANSCRIPTIONAL ACTIVITY INCREASING THE SENSITIVITY TO ASCORBATE OF ACUTE PROMYELOCYTIC LEUKEMIA CELLS. *CANCERS* 2020
2. IACCARINO L, OTTONE T, ALFONSO V, CICCONE L, DIVONA M, LAVORGNA S, **TRAVAGLINI S**, FERRANTINI A, FALCONI G, BEAR C, USAI M, FORGHIERI F, VENDITTI A, DEL PRINCIPE MI, ARCESE W, VOSO MT, HAFERLACH TORSTEN, LO-COCO F. MUTATIONAL LANDSCAPE OF PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA AT DIAGNOSIS AND RELAPSE. *AMERICAN JOURNAL OF HEMATOLOGY*. 2019
3. CIANGOLA G, GURNARI C, PATERNO G, MIRABILE M, ANGELINI M, LAVORGNA S, OTTONE T, **TRAVAGLINI S**, CICCONE L, LOCOCO F. STAT5B-RARA-POSITIVE ACUTE MYELOID LEUKEMIA: DIAGNOSTIC AND THERAPEUTIC CHALLENGES OF A RARE AML SUBTYPE. *LEUK RES*. 2019
4. IACCARINO L, DIVONA M, OTTONE T, CICCONE L, LAVORGNA S, CIARDI C, ALFONSO V, **TRAVAGLINI S**, FACCHINI L, CIMINO G, DI BONA E, VOSO MT, LO-COCO F. IDENTIFICATION AND MONITORING OF ATYPICAL PML/RARA FUSION TRANSCRIPTS IN ACUTE PROMYELOCYTIC LEUKEMIA. *GENES CHROMOSOMES CANCER*. 2019

5. PIREDDA ML, GAUR G, CATALANO G, DIVONA M, BANELLA C, **TRAVAGLINI S**, PUZZANGARA MC, VOSO MT, LO-COCO F, NOGUERA NI. PML/RARA INHIBITS EXPRESSION OF HSP90 AND ITS TARGET AKT. BR J HAEMATOL 2019
6. ALFONSO V, IACCARINO L, OTTONE T, CICCONI L, LAVORGNA S, DIVONA M, CAIROLI M, CRISTIANO A, CIARDI C, **TRAVAGLINI S**, FALCONI G, HASAN SK, VENDITTI A, ARCESE W, VOSO MT, LO-COCO F. EARLY AND SENSITIVE DETECTION OF PML A216V MUTATION BY DROPLET DIGITAL PCR IN 2 ATO RESISTANT ACUTE PROMYELOCYTIC LEUKEMIA. LEUKEMIA 2019
7. MASCIARELLI S, CAPUANO E, OTTONE T, DIVONA M, LAVORGNA S, LICCARDO F, ŚNIEGOCKA M, **TRAVAGLINI S**, NOGUERA NI, PICARDI A, PETROZZA V, FATICA A, TAMAGNONE L, VOSO MT, LO COCO F, FAZI F. RETINOIC ACID SYNERGIZES WITH THE UNFOLDED PROTEIN RESPONSE AND OXIDATIVE STRESS TO INDUCE CELL DEATH IN FLT3-ITD+ AML. BLOOD ADV. 2019

Rome, January 11th 2020

Serena Travaglini

AUTORIZZO IL TRATTAMENTO DEI DATI PERSONALI CONTENUTI NEL MIO CURRICULUM VITAE IN BASE ART. 13 DEL D. LGS. 196/2003